ArticleParasitology research2015
Terminalia ferdinandiana extracts as inhibitors of Giardia duodenalis proliferation: a new treatment for giardiasis.
Article in Parasitology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Liquid Chromatography-Mass Spectrometry Metabolomic Analysis ofMolecules (Basel, Switzerland) · 2025Article
- Green Synthesis ofBiomolecules · 2024Article
- Terminalia ferdinandiana Exell. extracts reduce pro-inflammatory cytokine and PGEInflammopharmacology · 2024Article
- Phytochemical Evaluation ofMolecules (Basel, Switzerland) · 2024Article
- Article
- Comparison of the antibacterial activity of Australian Terminalia spp. extracts against Klebsiella pneumoniae: a potential treatment for ankylosing spondylitis.Inflammopharmacology · 2022Article
- Ascorbic acid potentiates the Giardia duodenalis growth inhibitory activity of pure Terminalia ferdinandiana Exell compounds.Parasitology research · 2020Article
- Efficacy of Ageratum conyzoides extracts against Giardia duodenalis trophozoites: an experimental study.BMC complementary medicine and therapies · 2020Article
- The Therapeutic Properties of Plants Used Traditionally to Treat Gastrointestinal Disorders on Groote Eylandt, Australia.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Plants of the GenusFrontiers in pharmacology · 2020Review
- The Genus Terminalia (Combretaceae): An Ethnopharmacological, Phytochemical and Pharmacological Review.Natural products and bioprospecting · 2019Review
- Antioxidant Rich Extracts ofFoods (Basel, Switzerland) · 2019Article
- Endophytic Fungi fromJournal of fungi (Basel, Switzerland) · 2019Review
- Antigiardial Activity of Podophyllotoxin-Type Lignans from Bursera fagaroides var. fagaroides.Molecules (Basel, Switzerland) · 2017Article
- The medicinal properties and phytochemistry of plants of the genus Terminalia (Combretaceae).Inflammopharmacology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giardisis is a debilitating disease caused by gastrointestinal parasites of the genus Giardia. High-antioxidant T. ferdinandiana fruit extracts were investigated for the ability to block Giardia duodenalis growth. Methanolic and aqueous extracts had the most potent growth inhibitory activity (IC50 values of approximately 700 and 140 μg/ml, respectively). Ethyl acetate and chloroform extracts also inhibited G. duodenalis growth, albeit with lower potency. The hexane extract was completely devoid of G. duodenalis growth inhibitory activity. All extracts were nontoxic in the Artemia fransiscana bioassay. Nontargeted HPLC-quadrupole time-of-flight (QTOF) mass spectroscopy (with screening against three compound databases) putatively identified 17 compounds in all of the inhibitory extracts but not in the inactive hexane extract. The low toxicity of the Terminalia ferdinandiana fruit extracts and their potent G. duodenalis growth inhibitory bioactivity indicate their potential as medicinal agents in the treatment and prevention of this disease.
Indexed as
Identifiers
25876047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.